Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine

American Journal of Hematology

Volumn 84, Issue 12, 2009, Pages 790-794

  Lim, Ken H ^a,b   Pardanani, Animesh ^a   Butterfield, Joseph H ^a   Li, Chin Yang ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CLADRIBINE; CORTICOSTEROID; ETOPOSIDE; HYDROXYUREA; IMATINIB; MELPHALAN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CELL LINEAGE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; EOSINOPHILIA; FATIGUE; FEMALE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MAST CELL LEUKEMIA; MULTIPLE CYCLE TREATMENT; ONCOGENE; PERIPHERAL EDEMA; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; TET2 GENE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CLADRIBINE; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; JANUS KINASE 2; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MUTATION, MISSENSE; PIPERAZINES; POINT MUTATION; PREDNISONE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73349111582     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21561     Document Type: Article

References (36)

1. Patnaik MM, Rindos M, Kouides PA, et al. Systemic mastocytosis: A concise clinical and laboratory review. Arch Pathol Lab Med 2007;131:784-791.
2. Azana JM, Torrelo A, Mediero IG, et al. Urticaria pigmentosa: A review of 67 pediatric cases. Pediatr Dermatol 1994;11:102-106.
3. Middelkamp Hup MA, Heide R, Tank B, et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol 2002;16: 115-120.
4. Travis WD, Li CY, Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore). 1988;67:345-368.
5. Lawrence JB, Friedman BS, Travis WD, et al. Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991;91:612-624.
6. Lim K-H, Tefferi A, Lasho T, et al. Systemic mastocytosis in 342 consecutive adults. Blood 2009;113:5727-5736.
7. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-314.
8. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999;96:1609-1614.
9. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372.
10. Lim KH, Pardanani A, Tefferi A. KIT and mastocytosis. Acta Haematol 2008;119:194-198.
11. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
12. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453.
13. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004;11:58-64.
14. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-α: Results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:1090-1097.
15. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon a-2b in a patient with systemic mastocytosis. N Engl J Med 1992;326:619-623. 16. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998;138:489-495.
16. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon α-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res 2004;28:249-257.
17. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003;102:4270-4276.
18. Tefferi A, Li CY, Butterfield JH, et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001;344:307-309.
19. Pardanani A, Hoffbrand AV, Butterfield JH, et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004;28:127-131.
20. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-536.
21. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial. Cancer 2006;107:345-351.
22. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481-1484.
23. Valent P, Horny H-P, Li C-Y, et al. Mastocytosis (Mast Cell Disease). In: Jaffe E, Harris N, Stein H, Vardiman J, editors. WHO Classification of Tumours Pathology and Genetics Tumours of Haematopoetic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp 291-302.
24. Vardiman JW, Brunning RD, Arber DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp 18-30.
25. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23:900-904.
26. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
27. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/ MPN and AML. Leukemia 2009;23:1343-1345.
28. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038-3045.
29. Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: Assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008;83:457-459.
30. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22:660-664.
31. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-3225.
32. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686-692.
33. Lortholary O, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: A french multicenter study of 33 patients. ASH Annu Meeting Abstr 2004;104:661.
34. Penack O, Sotlar K, Noack F, et al. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. Ann Hematol 2005;84:692-693.
35. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008;14:3906-3915.
36. Gotlib J, George TI, Corless C, et al. The kit tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial. ASH Annu Meeting Abstr 2007;110:3536.